Endocrine Abstracts

Annual reports have been provided to the UK Acromegaly Database on 72 patients seen in Aberdeen during the past decade (41 women, mean age at diagnosis 47 yrs, mean GH at diagnosis 59 mU/l and 60% with macroadenomas). Thirty percent had glucose intolerance and 33% hypertension. Fifty-eight percent underwent surgery, 36% external radiotherapy (XRT, either alone or as adjuvant therapy) and 17% primary medical therapy (PMT, 4 had declined surgery). Thirty-seven percent are curren...

Background: Since receiving its UK licence in 1994, cabergoline [CAB] has become the dopamine agonist of choice for the management of hyperprolactinaemia in most UK endocrine units. Aim: To review the outcomes for the mother and neonate when CAB is taken during conception and into early gestation. Method: Retrospective review of Aberdeen casenotes from all hyperprolactinaemic women of childbearing age on CAB therapy and those of their live born infants. Results: Twenty women w...

Objective: To establish the efficacy of CAB as primary and exclusive therapy in the management of macroprolactinomasMethod: Retrospective case note review of all patients with macroprolactinomas treated with CAB since the drug received a UK licence in 1994. Patients: Sixteen patients (8males, 8 females) with mean age at presentation of 42.3yrs (range 22-72 years) were treated with initial CAB doses ranging from 0.5-1mg/week (median 1mg/week). Results: T...